Jean-Luc René Treillou

Deutsche Bank Securities, Inc. (DBSI) is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 1971 and is a wholly-owned investment banking and brokerage arm of DB U.S. Financial Markets Holding Corp., ultimately held by Deutsche Bank AG (NYSE: DB, FRA: DBK) in Germany. DBSI provides securities brokerage and investment advisory services to domestic and international private clients and institutions. They are also a primary dealer in US government securities as designated by the Federal Reserve.

Leonard Green & Partners LP (Leonard Green & Partners) is a private equity firm founded in 1989 by Leonard I. Green. The firm is headquartered in Los Angeles, California.

Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France.

IRDI Capital Investissement SAS(IRDI Capital) is an independent French regional venture capital/private equity firm which was established in 1981 by Alain Savary. The firm is headquartered in Toulouse.

Sud Ouest Capital Risque Innovation SAS invests in innovative companies established in the Aquitaine and Midi-Pyrénées regions. The fund invests in the range of €150,000 - €1 million per transaction and also makes co-investments.

Citoxlab France SAS operates as a research laboratory. It offers services in toxicology, genomics, pharmacology, pharmacokinetics, bio-analysis, ecotoxicology, stability testing and regulatory affairs. The company was founded in 1969 and is headquartered in Miserey, France.

Exane SA (Broker) (Exane) is the brokerage division of Exane SA, itself a subsidiary of Verner Investissements SAS in France. Established in 2004 as a joint venture between BNP Paribas and Verner Investissements, the firm is based in Paris and specializes in European equity research and broking activities. Exane has research centers in Paris and London which are supported by a team of economists and strategists.

PALUMED SA develops and produces pharmaceutical products for the treatment of Alzheimer's disease. The firm specializes in the development and production of new antimalarial agents and antibacterial molecules. The company was founded on December 8, 2000 and is headquartered in Castanet-Tolosan, France.

IXO Private Equity SAS (IXO-PE) is an independent France-based regional private equity firm which was founded in 2002. Headquartered in Toulouse with an office in Bordeaux, the firm was previously known as ICSO Gestion. Their culture emphasizes regional development and local employment creation. The firm manages FCPR limited partnership venture capital funds for institutions and FIP regional development funds for individual investors. IXO-PE's institutional clients include local collectivities, insurance companies and international corporations as well as regional, national and European banks.

BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development.

CU CHEMIE UETIKON GmbH engages in the production and development of active ingredients, pharmaceutical intermediates, as well as specialty chemicals for the chemical, pharmaceutical, and electronics industries. The company was founded on November 5, 1991 and is headquartered in Lahr, Germany.

Ffly4u SASU provides a low frequency localization services for mobile assets. It also offers services like movement, temperature, noise or opening detection in order to guarantee the integrity of sensitive assets. The company was founded by Pages Olivier in 2015 and is headquartered in Toulouse, France.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

Bionest Partners SAS operates as a global consulting firm which focuses on pharma, biotech, medical device and diagnostics. It offers strategy development, product planning and assessment services. The company was founded by Robert J. Easton and Alain J. Gilbert and is headquartered in Paris, France.

Owkin France SAS provides artificial intelligence for predictive medicine. The company was founded on September 7, 2016 and is headquartered in Paris, France.

Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France.

DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France.

Backbone SAS is a venture capital and private equity firm. It specializes in investments in late venture companies, startups, buyouts, growth financing, leveraged buyouts, and buyins. The company was founded by Nazanine Sahami on March 25, 2015 and is headquartered in Le Bouscat, France.

MicroPEP Technologies SAS engages in the development of biomimetic peptides that manage plant genetics. The company was founded by Thomas Laurent on April 15, 2016 and is headquartered in Toulouse, France.

Orano Med SAS is a French biotechnology company that utilizes nuclear technology to develop new therapies for cancer patients with resistant forms of cancer. The company is based in Châtillon, France, and the CEO of the company is Julien Dodet. The company specializes in targeted alpha therapy treatments, which combines biological molecules to target cancer cells with the properties of lead-212 (212pb) to destroy them while limiting the impact on surrounding healthy cells. Orano Med has formed collaborations with prestigious institutions and biopharmaceutical companies to develop several treatments using 212pb combined with various targeting agents. The company has 212pb manufacturing facilities, laboratories, and R&D centers in France and the United States and is currently investing to expand its GMP-manufacturing capacities for 212pb radiolabeled pharmaceuticals. Orano Med is ultimately controlled by the Government of France.

GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy.

Epsilen Bio SRL operates as a biotechnology company. It develops novel therapies based on epigenetic silencing. The company was founded by Angelo Lombardo and Luigi Naldini in December 2019 and is headquartered in Milan, Italy.

Swallis Medical SAS engages in the provision of diagnostic and monitoring solutions for problem of swallowing disorders. The company was founded by Linda Nicolini in 2019 and is headquartered in Toulouse, France.

IRDInov SAS functions as an investment holding French company. The private company is based in Paris, France.